The potential of merging these treatments was studied by Alimohammadi et al. in B16 mouse melanoma models where liposomal anti-CTLA-4 significantly delayed tumor growth when compared to standard anti-CTLA-4 combined with Doxil® (i.e., 113.3%, 22.86%, and 39.04%, respectively) [122]. The gene discussed is CTLA4; the disease is neoplasm.